Advent Computer Services Limited Overview
Advent Computer Services Limited is a Chennai-based legacy software company founded in 1984 by former IBM systems engineer Michael Arul. It started as a 100% export-oriented unit building business application software for IBM's midrange S/38 and, later, AS/400 platforms, and its flagship ADS 400 was a distribution and financial management suite. The company later tried several pivots: L&T Information Technology managed its operations under a 1999 MoU, it bought two small software firms in 2000, and in 2003 it pursued set-top-box and embedded technology with Tuxia GmbH and TVS Electronics. It most recently positioned itself in secure mobile banking and remote health monitoring. None of these produced meaningful revenue in recent years. Operating revenue fell from ₹0.48 Cr in FY2016 to zero in FY2020, and the board pursued a stated acquisition-led revival that was never executed. The equity was compulsorily delisted from BSE in November 2024. Today the company is best described as a dormant, foreign-promoter-controlled micro-entity whose main relevance to minority shareholders is the regulatory exit process.
The company's own description (latest annual report, FY2020)
The FY2020 Annual Report's statutory MGT-9 extract classifies the company's principal business as "Computer Programming, Consultancy and Related Activities" (NIC code 620) and gives no turnover percentage for it, because the company recorded no operating revenue in FY2020. The Management Discussion & Analysis (MD&A) in the same report frames the business plan in these terms (paraphrased):
-
The company needs to build execution capability in current IT and telecom platforms to win profitable project revenue. Management views acquiring existing companies with order books and proven delivery teams as the best route, and says it was qualifying one or more acquisition targets.
-
Management stated that it had identified investors willing to fund such acquisitions.
-
The company had been working to become the execution partner for an international company launching a secure mobile financial transaction platform for banks in India.
-
Long-term, it aims to leverage its mobile banking and payment platform technology. Short-term, it would take on any IT project that delivers revenue or profit. It also saw an opportunity in remote health monitoring services.
-
The main threat identified was the ability to raise capital for the acquisition strategy.
-
Human resources: the company outsources the manpower it needs, so its own headcount is very small.
The company's website, as summarised by Screener, describes two service lines:
-
Mobile Banking. The company claims access to telecom technologies and products that give it a competitive edge in delivering secure mobile banking services.
-
Remote Health / Telehealth. Independent remote and mobile health monitoring services meant to help physicians detect and analyse symptoms early. Listed offerings are remote and mobile ECG monitoring, voiding diary monitoring, blood pressure monitoring, blood glucose monitoring, fetus monitoring, intelligent infant management, and patient follow-up and medication management.
Business model and revenue model
| Dimension | Characterisation | Evidence |
|---|---|---|
| Revenue model (historical) | Software product licensing and implementation (ADS 400, retail and distribution packages) for export markets, plus IT services | Company history (1984–1999) |
| Revenue model (FY2016–FY2019) | Small IT consulting and support services. FY2019 sales and services were ₹10.69 lakh | AR FY2020 Directors' Report |
| Revenue model (FY2020 onward) | No operating revenue. FY2020 other income was ₹0.44 lakh | AR FY2020 |
| Product vs. service vs. subscription vs. licensing mix | Not disclosed by line. The single reported segment is software development and sale | PitchBook description; AR MGT-9 |
| Value-chain position | Historically an independent software vendor (ISV) inside the IBM midrange ecosystem. Recently an aspiring systems integrator or execution partner for third-party platforms (mobile banking) and a service provider using third-party telehealth devices and technology | AR FY2020 MD&A; company website summary |
| Customer types | Historically wholesale distribution and food manufacturing enterprises (e.g., the Australian beta site for a Bunge Corporation subsidiary) and large government or research computer installations in India. Recent customers not disclosed. FY2019 included a one-time related-party IT consulting contract with CCG Technologies India Pvt Ltd (value not disclosed) | ClearTax company background; AR FY2020 AOC-2 |
| End-markets | Banking and financial services (mobile banking), healthcare (remote monitoring), enterprise IT services | Company website; AR FY2020 MD&A |
| Geography | India only, per PitchBook. Foreign exchange earnings were nil in FY2020 | PitchBook; AR FY2020 Schedule E |
Independent characterisation
Based on the filings, Advent stopped being an operating software company in a commercial sense several years ago. The evidence is consistent across sources:
-
Operating revenue declined from ₹0.48 Cr (FY2016) to ₹0.46 Cr (FY2017), ₹0.16 Cr (FY2018), ₹0.11 Cr (FY2019) and nil (FY2020), with nil revenue in each of the first three quarters of FY2021 (Screener, from BSE filings).
-
Four employees at 31 March 2020, with delivery capacity outsourced (AR FY2020).
-
Zero R&D expenditure in FY2020 and no imported technology in the preceding three years (AR FY2020 Schedule E).
-
The Managing Director drew no remuneration because of losses (AR FY2020).
-
Unsecured borrowings rose from ₹0.73 Cr (FY2016) to ₹2.59 Cr (FY2020) and largely funded operating cash burn (Screener; AR MGT-9 indebtedness table).
-
The balance sheet is dominated by ₹12.96 Cr of fixed assets plus ₹3.85 Cr of capital work-in-progress, which were consolidated into ₹16.80 Cr of fixed assets by September 2020. Depreciation on these was essentially nil from FY2017 to FY2020 (Screener). Their nature is not specified in the sources reviewed. Analytically, they look like capitalised technology or marketing rights rather than productive tangible assets, and they produced no revenue.
In short, the "mobile banking" and "telehealth" positioning described aspirations, not operating businesses. With the November 2024 compulsory delisting, the company's status as a public-market entity has ended unless the delisting is reversed.
Strategy
Stated strategy (FY2020 Annual Report, paraphrased themes)
-
Acquisition-led capability building. Acquire IT/telecom companies with existing business and proven execution teams, so the company gains revenue, profit and delivery capability in the short term. Management said it was qualifying targets and had identified willing investors.
-
Execution partnership in mobile financial transactions. Become the Indian execution partner for an unnamed international secure mobile financial transaction platform for banks.
-
Remote health monitoring rollout. Pursue what management called a significant opportunity in remote health monitoring services.
-
Opportunistic IT projects. In the short term, take on any IT project that is revenue- or profit-accretive.
-
Cost discipline. Keep costs manageable given pandemic-era economic conditions.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
No strategic initiatives, partnerships, transformation programmes, ESG commitments, cost programmes or financial targets have been publicly announced by the company in this period. The only material corporate event found is BSE's compulsory delisting order effective 27 November 2024.
Management guidance and medium-term targets
Not publicly disclosed. The company has never issued quantitative revenue or margin guidance in the sources reviewed. The FY2020 MD&A expressed a qualitative view that the acquisition approach would reduce business and marketing risk.
Assessment
The strategy depended on external capital, which the MD&A itself named as the main threat. No acquisition, capital raise or platform contract was announced after September 2020, and the company subsequently fell out of listing compliance, so the stated strategy should be treated as unexecuted. The delisting removes the listed-equity currency that an acquisition strategy would normally rely on.
Products & Services
All products sit within the single software and IT services segment. The company does not disclose pricing, version years or revenue by product. Commercial status is shown as stated or inferred from filings.
Historical enterprise software (IBM midrange era)
| Product / offering | Description & capabilities | Target customer | Launch / latest year | Pricing | Commercial status |
|---|---|---|---|---|---|
| S/38 business application software | Export-oriented business application software for the IBM System/38 | Wholesale distribution enterprises using IBM S/38 | 1984–1988 | — | Legacy; superseded by ADS 400 |
| ADS 400 | Integrated distribution management and financial software for the IBM AS/400. Beta in Melbourne in 1991 at a Bunge subsidiary; launched in South East Asia in 1995 | Wholesale distributors and food manufacturers/distributors | Development from 1988; beta 1991; SE Asia launch 1995 | Not disclosed (licence-based, inferred) | No disclosed revenue in recent filings; presumed legacy/dormant |
| Retail & distribution packages | Proprietary packages for retail and distribution businesses | Indian and overseas retailers and distributors | 1,996 | — | No disclosed recent revenue |
Embedded and consumer-electronics technology (2003 initiative)
| Product / offering | Description & capabilities | Target customer | Year | Pricing | Commercial status |
|---|---|---|---|---|---|
| Tuxia-based set-top box technology | Advent was to supply Tuxia GmbH (Germany) technology for set-top boxes built to Advent's specifications by TVS Electronics, with planned capacity scaling to 60,000 units per month | Indian and global set-top box market | 2003 MoU | — | Outcome not publicly disclosed; no related revenue in recent filings |
| Exclusive Indian marketing rights to Tuxia products and technologies | Rights acquired through the issue of 1.84 million shares to CCG Global Ltd (Mauritius), plus five years of support and upgrades through 0.46 million shares to Tuxia GmbH | — | 2,003 | Share-settled | Status not disclosed |
Mobile banking
| Offering | Description & capabilities | Target customer | Year | Pricing | Commercial status |
|---|---|---|---|---|---|
| Secure mobile banking / mobile financial transaction services | Company claims access to telecom technologies and products for secure mobile banking. MD&A FY2020 says it aimed to be the Indian execution partner for an international company's secure mobile financial transaction platform for banks (partner not named) | Indian banks | Positioning since at least the late 2010s (exact year not disclosed) | — | Pre-revenue; no contract disclosed |
Remote health monitoring (telehealth)
| Offering | Description | Target customer | Status |
|---|---|---|---|
| Remote & Mobile ECG Monitoring System | Remote cardiac rhythm monitoring for physician review | Physicians, hospitals, patients with cardiac conditions | Listed on website; no disclosed revenue |
| Remote & Mobile Voiding Diary Monitoring System | Remote urological voiding diary capture | Urologists and patients | Listed; no disclosed revenue |
| Remote & Mobile Blood Pressure Monitoring System | Remote BP tracking | Hypertension patients and clinicians | Listed; no disclosed revenue |
| Remote & Mobile Blood Glucose Monitoring System | Remote glucose tracking | Diabetes patients and clinicians | Listed; no disclosed revenue |
| Remote & Mobile Fetus Monitoring System | Remote fetal monitoring | Obstetricians and expectant mothers | Listed; no disclosed revenue |
| Remote & Mobile Intelligent Infant Management System | Infant health monitoring and management | Paediatric care providers and parents | Listed; no disclosed revenue |
| Patient Follow-up & Medication Management System | Post-discharge follow-up and medication adherence | Hospitals and clinics | Listed; no disclosed revenue |
Specifications, device partners, regulatory approvals (e.g., CDSCO medical-device registration) and launch years for the telehealth systems are not publicly disclosed. The FY2020 MD&A calls remote health monitoring an opportunity, not an operating line.
IT consulting and support services
| Offering | Description | Evidence |
|---|---|---|
| IT consulting & support for graphical user interface (GUI) | One-time related-party contract with CCG Technologies India Pvt Ltd (in which the MD has significant influence), approved by the board on 30 May 2019. Value not disclosed | AR FY2020 Form AOC-2 |
| General IT projects | MD&A: short-term opportunity to take on any IT project that delivers revenue or profit | AR FY2020 MD&A |
Financial Narrative
Income statement
Sources: Screener P&L; AR FY2020 Directors' Report (FY2020 total income ₹0.44 lakh, total expenditure ₹19.60 lakh, loss ₹19.16 lakh; FY2019 total income ₹10.69 lakh, expenditure ₹54.41 lakh, loss ₹43.72 lakh). Gross profit is not reported because the company presents no cost-of-goods line. Diluted EPS equals basic: no dilutive instruments were outstanding, and the AR confirms no convertible warrants.
Margins and growth
Revenue growth for FY2016 is computed on FY2015 revenue of ₹0.31 Cr (Screener). Margins are undefined in FY2020 because revenue was zero. Revenue CAGR FY2016–FY2019 (3 years) is approximately -38.8% a year (computed: (0.11/0.48)^(1/3) − 1). The FY2016–FY2020 CAGR is not meaningful (terminal revenue zero). Screener reports TTM sales growth of -100% and 10-year compounded profit growth of -3%.
Balance sheet
Sources: Screener balance sheet; AR FY2020 MGT-9 indebtedness table. Unsecured loans were ₹24,382,129 at 1 April 2019 and ₹25,936,082 at 31 March 2020, with no secured loans or deposits. The short/long split and the lender identity were not found in the extracts reviewed. Screener shows total borrowings of ₹2.65 Cr against the AR's ₹2.59 Cr of unsecured principal; the difference may be other borrowing-type liabilities. Book value per share is computed as net worth ÷ 16.27 million shares; Screener shows ₹8.77 (latest). The working capital proxy is an analytical approximation from aggregated lines, not a reported figure. Sundry debtors were ₹82.15 lakh at 31 Mar 2020 (AR MD&A). Cash and equivalents are not separately disclosed in the sources reviewed. At 30 Sep 2020 the half-year balance sheet showed fixed assets of ₹16.80 Cr and CWIP of nil (CWIP capitalised), net worth of about ₹14.28 Cr and borrowings of ₹2.66 Cr.
Cash flow
Source: Screener cash flow (from BSE filings). The AR FY2020 confirms nil expenditure on fixed assets in FY2020, no dividend, and no buyback.
Ratios
ROE, ROA, debt/equity and asset turnover are computed from the tables above (year-end balances). ROCE, debtor days and cash conversion cycle come from Screener; the CCC equals debtor days because there are no inventories or payables days. ROIC and current ratio are not computed because the asset/liability split is undisclosed. Net debt/EBITDA is not meaningful (negative EBITDA, cash undisclosed). FY2019 interest coverage is undefined (interest rounds to zero). Interest coverage FY2018 = -0.52/0.03; FY2020 = -0.18/0.01 (approximate, rounded inputs).
Partial FY2021 (latest available interim data)
Source: Screener quarterly results (BSE filings). Trailing-twelve-month net loss to Dec 2020: ₹0.16 Cr. No later results were located.
Commentary: trends, inflections and drivers
Revenue collapse (FY2017–FY2020). FY2016 was the last year with revenue near ₹0.5 Cr, and the company was only marginally profitable at a ₹0.02 Cr operating profit. The FY2018 inflection, when revenue fell 65% to ₹0.16 Cr, coincided with a sharp rise in the cost base (expenses rose to ₹0.65 Cr from ₹0.45 Cr). The result was the largest loss in the dataset, ₹0.52 Cr. Revenue then fell to ₹10.69 lakh in FY2019 and to zero in FY2020. The AR attributes no specific cause beyond calling the year "challenging". Analytically, the drivers were the end of legacy service contracts, no new product traction in mobile banking or telehealth, and a deliberate shift to an acquisition-led strategy that was never funded.
Cost containment (FY2020–FY2021). Expenses fell 67% in FY2020 (₹54.41 lakh to ₹19.60 lakh), which narrowed the loss to ₹19.16 lakh. The MD drew no salary. The two KMPs (CFO and Company Secretary) were each paid ₹1.81 lakh, and independent directors received sitting fees of ₹2,000 per meeting. Quarterly costs of ₹2–8 lakh in FY2021 suggest the company was being run mainly to keep listing compliance alive.
Funding of losses through unsecured debt. Cumulative operating cash burn of about ₹1.88 Cr over FY2017–FY2020 was funded almost entirely by financing inflows of about ₹1.92 Cr, with unsecured borrowings rising more than 3.5x from ₹0.73 Cr to ₹2.65 Cr. Leverage is modest against the book equity of ₹14.33 Cr, but that equity is itself backed largely by non-earning fixed assets (see below), so economic leverage is materially higher than the 0.18x book ratio suggests.
Asset quality: the central analytical issue. Of the ₹17.88 Cr asset base at FY2020, ₹16.81 Cr (94%) is fixed assets plus CWIP that have generated no revenue and attracted essentially no depreciation since FY2017. The auditor's report carried no qualification for FY2020 (AR Directors' Report). Even so, an asset base of this size with no amortisation, alongside zero revenue, raises a significant question of whether an impairment test under Ind AS 36 would support the carrying value. If these assets were fully impaired, net worth would turn negative (about -₹2.5 Cr). The nature of the assets is not disclosed in the sources reviewed. A plausible link to the 2003 share-settled acquisition of Tuxia marketing rights and to the CWIP capitalised in FY2011 and again in H1 FY2021 is an analytical inference, not a disclosed fact.
Receivables risk. Sundry debtors of ₹82.15 lakh at March 2020 were about 7.7x FY2019 revenue, and Screener's debtor days rose from 175 (FY2016) to 2,920 (FY2019). Analytically, these receivables are probably stale and of doubtful recoverability.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Revenue by Segment (%)
| Metric | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
Software development & services segment revenue (INR Cr) | 0.16 | 0.11 | 0.00 |
Segment share of total operating revenue (%) | 100 | 100 | 100 |
Segment operating profit (EBITDA, INR Cr) | -0.49 | -0.43 | -0.18 |
Segment pre-tax profit (INR Cr) | -0.52 | -0.43 | -0.19 |
Segment operating margin (%) | -306.25 | -390.91 | — |
Segment revenue YoY growth (%) | -65.22 | -31.25 | -100.00 |
Income Statement and Per-Share Data
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 0.48 | 0.46 | 0.16 | 0.11 | 0.00 |
Other income (INR Cr) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0044 |
Total expenses excl. interest & depreciation (INR Cr) | 0.46 | 0.45 | 0.65 | 0.54 | 0.18 |
EBITDA / operating profit (INR Cr) | 0.02 | 0.01 | -0.49 | -0.43 | -0.18 |
Depreciation (INR Cr) | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest (INR Cr) | 0.00 | 0.00 | 0.03 | 0.00 | 0.01 |
Profit before tax (INR Cr) | 0.01 | 0.01 | -0.52 | -0.43 | -0.19 |
Tax (INR Cr) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net profit (INR Cr) | 0.01 | 0.00 | -0.52 | -0.44 | -0.19 |
EPS basic (INR) | 0.01 | 0.00 | -0.32 | -0.27 | -0.12 |
EPS diluted (INR) | 0.01 | 0.00 | -0.32 | -0.27 | -0.12 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 54.84 | -4.17 | -65.22 | -31.25 | -100.00 |
EBITDA margin (%) | 4.17 | 2.17 | -306.25 | -390.91 | — |
Operating (EBIT) margin (%) | 2.08 | 2.17 | -306.25 | -390.91 | — |
Net margin (%) | 2.08 | 0.00 | -325.00 | -400.00 | — |
Balance Sheet and Per-Share Data
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 17.21 | 17.64 | 18.31 | 18.02 | 17.88 |
Fixed assets, net (INR Cr) | 12.96 | 12.96 | 12.96 | 12.96 | 12.96 |
Capital work-in-progress (INR Cr) | 3.85 | 3.85 | 3.85 | 3.85 | 3.85 |
Other assets incl. receivables & cash (INR Cr) | 0.40 | 0.83 | 1.50 | 1.21 | 1.07 |
Equity share capital (INR Cr) | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 |
Reserves & surplus (INR Cr) | -0.79 | -0.79 | -1.31 | -1.75 | -1.94 |
Total equity / net worth (INR Cr) | 15.48 | 15.48 | 14.96 | 14.52 | 14.33 |
Total borrowings (INR Cr) | 0.73 | 1.26 | 2.44 | 2.59 | 2.65 |
Other liabilities (INR Cr) | 1.00 | 0.90 | 0.91 | 0.91 | 0.90 |
Approx. working capital = other assets − other liabilities (INR Cr) | -0.60 | -0.07 | 0.59 | 0.30 | 0.17 |
Book value per share (INR) | 9.51 | 9.51 | 9.19 | 8.92 | 8.81 |
Cash Flow
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 0.00 | -0.53 | -0.62 | -0.60 | -0.13 |
Capex / investing cash flow (INR Cr) | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 |
Free cash flow (INR Cr) | -0.01 | -0.53 | -0.62 | -0.61 | -0.13 |
Financing cash flow (INR Cr) | 0.00 | 0.53 | 1.18 | 0.16 | 0.05 |
Net change in cash (INR Cr) | -0.01 | 0.00 | 0.56 | -0.45 | -0.08 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
ROE (%) | 0.06 | 0.00 | -3.48 | -3.03 | -1.33 |
ROA (%) | 0.06 | 0.00 | -2.84 | -2.44 | -1.06 |
ROCE (%) (Screener) | 0.06 | 0.06 | -2.87 | -2.49 | -1.06 |
Debt / equity (x) | 0.05 | 0.08 | 0.16 | 0.18 | 0.18 |
Interest coverage (EBIT/interest, x) | — | — | -17.33 | — | -18.00 |
Asset turnover (x) | 0.028 | 0.026 | 0.009 | 0.006 | 0.000 |
Debtor days | 174.90 | 531.63 | 1,756.56 | 2,920.00 | — |
Cash conversion cycle (days) | 174.90 | 531.63 | 1,756.56 | 2,920.00 | — |
Income Statement and Per-Share Data (Quarterly)
| Metric | Q1FY2021 | Q2FY2021 | Q3FY2021 |
|---|---|---|---|
Revenue (INR Cr) | 0.00 | 0.00 | 0.00 |
Expenses (INR Cr) | 0.02 | 0.03 | 0.08 |
Net profit (INR Cr) | -0.02 | -0.03 | -0.08 |
EPS (INR) | -0.01 | -0.02 | -0.05 |
Revenue by Region and Revenue by Region (%)
| Region | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
India revenue (INR Cr) | 0.16 | 0.11 | 0.00 |
Overseas revenue (INR Cr) | — | — | 0.00 |
India share of revenue (%) | 100 | 100 | — |
Capital Markets
| Item | Detail |
|---|---|
Current listing | Delisted from BSE effective 27 Nov 2024; on BSE Dissemination Board |
Last traded price | ₹2.82 (28 Feb 2022) |
Implied market cap at last trade | ₹4.59 Cr |
Price/book at last trade | 0.32x (Screener, book value ₹8.77) |
52-week range (as last captured by an aggregator) | ₹4.52 high / ₹1.37 low (date basis unclear) |
1-year / 3-year / 5-year performance (to Oct 2026) | Not meaningful: no trading since Feb 2022. Screener shows 5-year stock price CAGR of 2% and 10-year of 0% (as of last trade) |
Analyst consensus | None. No sell-side coverage. Trendlyne shows an informal community poll (3 votes: 33% buy, 67% hold), which is not analyst coverage |
Dividend history | No dividends in any year FY2009–FY2020 (payout 0%; Screener; AR FY2020) |
Dividend policy | Not formally disclosed; dividends withheld due to losses |
Bonus / split / rights | 3:4 bonus (23 Aug 1993); no split since 2000; no rights issue since 2000 (Trendlyne; Goodreturns) |
Credit ratings (Moody's / S&P / Fitch / Indian agencies) | None. The AR states no debt instruments were issued and no credit ratings obtained |
Debt maturity profile | Not disclosed. All borrowings unsecured (₹2.59 Cr principal at 31 Mar 2020); no interest due but unpaid |
Share Price
| Metric | Apr2019 | May2019 | Jun2019 | Jul2019 | Aug2019 | Sep2019 | Oct2019 | Nov2019 | Dec2019 | Jan2020 | Feb2020 | Mar2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share price high (INR) | 1.94 | 2.10 | 2.31 | 1.81 | 0.88 | 0.78 | 0.75 | 1.26 | 1.72 | 1.72 | 1.77 | 1.53 |
Share price low (INR) | 1.94 | 1.94 | 1.90 | 0.92 | 0.72 | 0.69 | 0.68 | 0.71 | 1.32 | 1.69 | 1.53 | 1.33 |
Valuation Multiples
| Multiple | Advent (at last trade, Feb 2022) | Peers |
|---|---|---|
P/E | Not meaningful (losses) | Not compiled (Advent not comparable) |
EV/EBITDA | Not meaningful (negative EBITDA) | Not compiled |
EV/Sales | Not meaningful (zero sales) | Not compiled |
P/B | 0.32x | Not compiled |
Analyst Conclusions
Management guidance and consensus
Management guidance: None quantitative. The latest qualitative outlook (FY2020 MD&A) expected an acquisition-led revival that has not materialised.
Consensus growth expectations: None (no analyst coverage).
Bull case (three arguments grounded in data)
-
Statutory exit at fair value could exceed the last traded price. Book value per share was about ₹8.8 at FY2020 against a last trade of ₹2.82 (0.32x P/B). If an independent valuer were to attribute value to the ₹16.8 Cr fixed-asset base, a promoter-funded exit could deliver a premium to minority holders.
-
Balance-sheet leverage is modest and cash burn has been cut to a minimum. Borrowings of ₹2.65 Cr against net worth of ₹14.33 Cr, and a FY2020 operating cash outflow of only ₹0.13 Cr, mean the company can stay dormant cheaply while the promoter decides its future.
-
Target markets are growing quickly. Indian telemedicine is estimated at USD 3.1 billion in 2024, growing about 20.5% a year (IMARC). If the promoter group (CCG GmbH and related CCG entities) injected a real telehealth or mobile-payments business, the corporate vehicle could be revived.
Bear case (three arguments grounded in data)
-
There is no operating business. Revenue fell to zero in FY2020 and stayed there through 9M FY2021, with four employees and nil R&D. No product, contract or partnership has been announced in nearly six years.
-
Reported equity likely overstates economic value. 94% of assets (₹16.81 Cr) are non-earning fixed assets/CWIP with no depreciation for years, and receivables of ₹82 lakh are about 7.7x the last annual revenue. A realistic impairment would turn net worth negative, which undermines both the bull-case fair value and any exit premium.
-
Governance and compliance failures culminated in compulsory delisting. These include the 2015 suspension, exchange fines, late ROC filings, a disqualified director, no annual report after FY2020, and delisting in November 2024. Minority holders now hold an illiquid security whose realisation depends on promoter compliance with exit obligations.
Key catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Independent valuer's fair-value determination and any promoter exit offer under the Delisting Regulations | Determines the realisable value for minority shareholders |
| MCA filings (AOC-4, MGT-7) for FY2021–FY2026 | Shows whether the company remains compliant and active, or risks penalties or strike-off |
| Board composition and CMD status after the Mar 2024 term expiry | Key-person and governance continuity |
| Any statement or transaction by CCG GmbH (53.83% promoter) | The promoter is the only party able to fund an exit or a revival |
| Any SEBI or exchange enforcement on non-compliant promoters/directors | Escalation risk |
| Dissemination Board disclosures or matched off-market trades | Only remaining price-discovery mechanism |
Concluding analyst verdict
Advent Computer Services Limited is no longer an investable operating company in any conventional sense. It is a 42-year-old corporate vehicle that once had a respectable niche, exporting distribution software for IBM's midrange platforms from Madras in the 1980s and 1990s, and then spent the following two decades on pivots that never generated durable revenue. The ADS 400 franchise faded with its platform. The L&T operating MoU, the 2000 acquisitions, the 2003 Tuxia/TVS set-top-box venture, and the later mobile-banking and telehealth positioning left little trace in the income statement. By FY2020 operating revenue was zero, headcount was four, R&D was nil, and losses were being funded through unsecured loans.
The balance sheet looks solvent on paper, with net worth of ₹14.33 Cr and debt/equity of 0.18x. That comfort is largely illusory: about ₹16.8 Cr of non-earning, unamortised fixed assets carry nearly all the book equity, and receivables appear stale. Governance was weak and compliance chronically late, a pattern that ended in BSE's compulsory delisting effective 27 November 2024. No annual report or quarterly result has been found for any period after December 2020.
For a remaining minority shareholder, the relevant question is not growth or valuation multiples but enforcement. Will the promoter group, led by CCG GmbH with 53.83%, deliver the exit option required by the SEBI Delisting Regulations, and at what independently determined fair value? Until that is resolved, the security is illiquid, informationally opaque and dependent on regulatory action. Any revival thesis would require a promoter asset injection and relisting, for which there is no public evidence.
Verdict: non-investable dormant entity. Monitor solely for exit-offer and regulatory developments. Every operating-business scenario should be treated as speculative and unsupported by disclosed facts.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | DIN | Role | Appointed | Tenure (to Oct 2026, if still serving) | Background / education | Age | FY2020 compensation |
|---|---|---|---|---|---|---|---|
Michael Arul | 00,885,978 | Chairman & Managing Director (promoter) | 22 Feb 1984 | 42+ years | B.E. (Industrial Production), College of Engineering, Guindy. Former IBM systems engineer (marketing division). Later worked on M&A of software/technology companies in the USA, UK, Australia and Germany. Helped bring supercomputing platforms to NIC, TIFR and the Department of Space. Set up India's first IBM S/38 and AS/400 export software development centres. Other directorships: CCG Technologies India Pvt Ltd, Tecways India Pvt Ltd | 80 (born 11 Mar 1946) | Nil (no remuneration due to losses) |
Shree Kumar Narayan | 07,438,879 | Independent Director; Chair of Audit, NRC and SRC | 13 Apr 2016 (MCA record shows 28 Sep 2016) | 10 years | — | — | Sitting fees ₹8,000 |
Kavitha | 07,929,620 | Independent Director (woman director) | 22 Sep 2017 | 9 years | — | — | Sitting fees ₹6,000 |
Parthasarathy Sethuraman | 08,278,159 | Independent Director | 13 Nov 2018 | 7+ years | — | — | Sitting fees ₹8,000 |
Virginie Bompoil | 08,104,837 | Independent Director (woman director) | 13 Nov 2018 | 7+ years | — | — | Sitting fees ₹8,000 |
G. (Ganapathi) Swaminathan | 08,829,718 | Additional (Independent) Director; proposed for a 5-year term to Sep 2025 | 20/25 Aug 2020 | Term ended Sep 2025 (if confirmed) | Graduate. Legal drafting experience (affidavits, petitions, writs, appeals). Long association with the Directorate of Millets Development, Government of India | 75 (born 29 Aug 1951) | Not applicable for FY2020 |
Shaji John Abraham | 01,454,398 | Independent Director | — | Ceased 27 Sep 2019 (tenure completed) | — | — | Sitting fees ₹4,000 |
Samir Harakhchand Shah | 05,192,199 | Non-executive, non-independent | 22 Sep 2017 | Ceased 8 May 2020 (disqualified under Sec 164(2)) | Not disclosed; held 35,240 shares | — | Nil |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Title | FY2020 remuneration (INR) |
|---|---|---|
Michael Arul | Chairman & Managing Director | 0 |
Rahul Jain | Chief Financial Officer | 181,200 |
Vishal Desai | Company Secretary & Compliance Officer | 181,200 |
Directors' Remuneration
| Feature | Detail |
|---|---|
Board size (31 Mar 2020) | 6: 1 executive, 4 independent (incl. 2 women), 1 non-executive non-independent |
Chair/CEO separation | No. Michael Arul is both Chairman and Managing Director |
Board meetings FY2020 | 4 (30 May 2019, 14 Aug 2019, 13 Nov 2019, 11 Feb 2020); separate independent directors' meeting 11 Feb 2020 |
Audit Committee | Chair: Shree Kumar Narayan. Members: Michael Arul (executive), P. Sethuraman, Kavitha, Virginie Bompoil; earlier Shaji John Abraham and Samir Shah. 4 meetings |
Nomination & Remuneration Committee | Chair: Shree Kumar Narayan. Members: P. Sethuraman, Virginie Bompoil, Kavitha and Michael Arul (inducted 13 Nov 2019). 4 meetings |
Stakeholders' Relationship Committee | Chair: Shree Kumar Narayan. Members: P. Sethuraman, Virginie Bompoil, Michael Arul. 4 meetings. Nil investor complaints received or pending |
Governance observations | The executive MD sits on the Audit Committee and the NRC. Best practice would have NRC membership wholly non-executive, and Regulation 19 requires all NRC members to be non-executive. A director was disqualified by MCA (Section 164(2), typically triggered by non-filing at another company). BSE previously fined the company for audit committee composition (Q2 FY2019) and for a late annual report (FY2019); both fines were waived |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
27 Sep 2019 | Shaji John Abraham ceases as Independent Director | Completion of tenure |
8 May 2020 | Samir H. Shah ceases | Disqualification under Sec 164(2) |
20/25 Aug 2020 | G. Swaminathan appointed Additional Independent Director | Board refresh |
30 Sep 2020 (AGM) | Michael Arul re-appointment proposed as CMD, 12 Mar 2021–11 Mar 2024, with remuneration only from surplus profits | Continuation of founder leadership |
11 Mar 2024 | Arul's approved term as CMD expired. Any further re-appointment is not publicly disclosed | — |
After 2020 | No disclosed changes; MCA/aggregator records list five directors | — |
Major Shareholders
| Holder | Shares | Stake (%) | Category |
|---|---|---|---|
CCG GmbH | 8,760,000 | 53.83 | Promoter (foreign body corporate) |
Michael Arul | 52,077 | 0.32 | Promoter (individual) |
Astra Merchandising Pvt Ltd | 355,149 | 2.18 | Public (body corporate) |
Durga Prasad T | 184,512 | 1.13 | Public (individual) |
K Gurava Reddy | 175,000 | 1.08 | Public (individual) |
Sujana B | 153,385 | 0.94 | Public (individual) |
Mahaveer S Danigond | 145,000 | 0.89 | Public (individual) |
Kishor Pravinchandra Parikh | 116,059 | 0.71 | Public (individual) |
Jash Niral Shah | 115,000 | 0.71 | Public (individual) |
Hitesh Rasiklal Thakker | 109,735 | 0.67 | Public (individual) |
Chakrikaa SR | 102,580 | 0.63 | Public (individual) |
Anil Mohanlal Thakker | 87,000 | 0.53 | Public (individual) |
Governance Detail
| Category | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|
Promoters (%) | 53.83 | 54.15 | 54.15 | 54.15 |
DIIs (%) | 0.20 | 0.20 | 0.20 | 0.20 |
Public (%) | 45.97 | 45.65 | 45.65 | 45.65 |
Number of shareholders | 9,314 | 8,952 | 8,929 | 8,925 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Description | Relative positioning vs. Advent |
|---|---|---|---|
Banking/fintech software (India) | Nucleus Software Exports | Lending and transaction banking software products | Established product company; FY2025 consolidated revenue about ₹839 Cr |
Banking/fintech software | Intellect Design Arena | Banking, insurance and capital markets software (eMACH.ai, Purple Fabric) | FY2025 total income about ₹2,577 Cr |
Banking/fintech software | Infosys Finacle (Infosys) | Core and digital banking platform | Global scale leader |
Banking/fintech software | TCS BaNCS (Tata Consultancy Services) | Banking and financial services platform | Global scale leader |
Mobile banking/payments enablement | 3i Infotech | Banking and financial services IT products and services | Listed mid-tier peer |
Enterprise ERP/distribution software (historical ADS 400 market) | Ramco Systems | Chennai-based ERP, HR/payroll and aviation software | FY2025 revenue ₹5.91b; FY2026 revenue about ₹701 Cr |
Enterprise ERP/distribution (historical) | Infor (successor to Intentia's M3 via Lawson) | Global ERP vendor; Intentia was an Advent distribution partner in 1995 | Global leader (private) |
Telehealth / remote monitoring | Apollo 24/7 (Apollo Hospitals) | Integrated digital health and teleconsultation | Scale leader in Indian digital health |
Telehealth | Practo | Teleconsultation and clinic software (private) | Major consumer health platform |
Telehealth | Tata 1mg | E-pharmacy and teleconsultation (private, Tata Digital) | Major consumer health platform |
Remote monitoring devices | Dozee (private) | Contactless remote patient monitoring | Specialist RPM provider |
Small-cap IT services | Saksoft, Kellton Tech Solutions | Digital IT services | Operating small-caps with real revenue |
Competitive Advantages & Vulnerabilities
| Advantages (limited) | Vulnerabilities (severe) |
|---|---|
Founder with long industry history (ex-IBM, 40+ years) and links to a foreign promoter group (CCG GmbH) | No revenue, four employees and outsourced delivery: no capability to compete for bank or healthcare contracts |
Modest book leverage (debt/equity 0.18x at FY2020) | Delisted. Cannot use listed equity for acquisitions or capital raising, and faces regulatory debarment consequences |
Historical credibility in the enterprise software export niche (1980s–1990s) | Zero R&D, no patents, no disclosed proprietary platform in mobile banking or telehealth |
| — | Stale receivables (₹82 lakh) and large non-earning fixed assets (₹16.8 Cr) |
Peer Comparison FY2025
| Metric | Advent Computer Services (FY2020, last audited) | Nucleus Software Exports (FY2025) | Intellect Design Arena (FY2025) | Ramco Systems (FY2025) |
|---|---|---|---|---|
Revenue (INR Cr) | 0.00 | 838.70 | 2577.03 (total income) | 591 (revenue); 596.9 (consolidated income) |
Revenue growth YoY (%) | -100.0 | 2.8 | 0.45 (total income) | 13 |
Net profit (INR Cr) | -0.19 | 161.76 | 332.77 | -34.25 |
Net margin (%) | n/m | about 19 | about 13 | about -6 |
R&D intensity (% of revenue) | 0 (nil R&D) | — | — | — |
Recent Developments
Searches of BSE-mirrored aggregators (Screener, Trendlyne), news databases and corporate-registry aggregators found no company-originated material developments between April 2025 and October 2026**: no product launches, contract wins, results, guidance, leadership changes, litigation or restructurings. Trendlyne shows no mutual fund holdings in every month from July 2023 to October 2026, and no bulk/block deals or insider/SAST disclosures.



